6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer (related to financial reporting)
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
F-1: Registration statement for securities of certain foreign private issuers
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
20-F: Registration statement / Annual report / Transition report
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) | 6-K: Report of foreign private issuer (related to financial reporting)
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) | D: Filing D
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(9.9%),Lind Global Partners II LLC(9.9%), etc.
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) | 424B5: Prospectus
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) | 6-K: Report of foreign private issuer (related to financial reporting)
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS PHARMACEUTICS LTD C/WTS 25/09/2025(TO PUR COM) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
No Data